| dc.description.abstract | Background: Diabetes mellitus is a chronic disease that occurs when the pancreas
does not produce enough insulin or when the body cannot use the insulin produced
effectively. Breadfruit leaves are used as antidiabetics in the presence of bioactive
components such as flavonoids. One of the receptors that play a role in the treatment
of diabetes is PPAR-γ.
Objective: To determine the secondary metabolites of ethanol breadfruit leaves
extract of against PPAR-γ receptors that have potential as antidiabetics in silico and
in vivo.
Methods: The stages of this study include LC-HRMS/MS analysis, in silico testing
includes prediction of biological activity (PASS online), physicochemistry (Drug
design Lipinski), pharmacokinetics (SwissADME), toxicity (ProTox-II) and
molecular docking (Autodock tools and Autodock vina), in vivo testing used
animals (zebrafish), with parameters fasting blood glucose levels, and data analyzed
using One way ANOVA.
Results: In silico, the chemical compounds of breadfruit leaves that have
interactions with PPAR-γ receptors by looking at the low docking score and have
the same amino acid residues as the comparator are Apigenin-7-o-glucoronide,
Tiliroside, Phloretin, and Artocarpin. In vivo, ethanol extract of breadfruit leaves
has antidiabetic activity to reduce blood glucose levels of zebrafish, while
maintaining the number of islets of Langerhans at doses of 200, 300, and 400 mg.
Conclusion: From the results of this study, it is known that ethanol extract of
breadfruit leaves has activity as an antidiabetic proven in silico and in vivo. | en_US |
